Fish oil reduces heart rate and oxygen consumption during exercise
Participants
n=16 well-trained male cyclists who completed the study
Control (olive oil): n=7, age 27.1 ± 2.7 years; Fish oil: n=9, age 23.2 ± 1.2 years
VO2peak: control 66.8 ± 2.4 → 67.2 ± 2.3; fish oil 68.3 ± 1.4 → 67.2 ± 1.2 mL/kg/min (pre → post)
Protocol (8-week RCT, from the abstract)
Design: double-blind, parallel groups, randomised
Supplement: 8 × 1 g capsules per day of fish oil (FO) or olive oil (control) for 8 weeks; the abstract does not give EPA/DHA content
Tests, before and after supplementation: peak O2 consumption test (VO2peak) on an electronically braked cycle ergometer, and a sustained submaximal test at 55% of peak workload
Measures: whole-body O2 consumption; indirect indices of myocardial O2 consumption — heart rate and rate-pressure product (RPP); erythrocyte membrane omega-3 content
Rationale: omega-3 PUFAs incorporate into heart and skeletal-muscle membranes, and in animal hearts reduce O2 consumption
Key Results (from the abstract)
| Outcome | Result |
|---|---|
| Erythrocyte omega-3 content | Increased with fish oil |
| VO2peak, peak workload | No difference after supplementation |
| Heart rate during incremental test to exhaustion (incl. peak HR) | Lower with fish oil (P < 0.05) |
| Steady-state submaximal HR, whole-body VO2, RPP (55% peak workload) | Lower with fish oil (P < 0.01) |
| Time to voluntary fatigue | Not altered |
The abstract gives no beats-per-minute or mL/kg/min differences for the submaximal effects; only the direction and P-values.
Critical Finding: Fish oil lowered heart rate (including peak HR), submaximal whole-body O2 consumption and rate-pressure product without any change in VO2peak, peak workload or time to fatigue — lower whole-body and myocardial O2 demand at the same work, i.e. an economy effect, not a capacity effect.
Mechanism (as framed by the authors)
Omega-3 PUFAs are readily incorporated into heart and skeletal-muscle membranes; animal studies show reduced myocardial O2 consumption. The human data here point the same way: less O2 for the same external work, in the heart (HR, RPP) and the whole body (VO2 at 55% peak workload).
The effect is on demand, not on maximal capacity (VO2peak unchanged).
Membrane-fluidity, arterial-stiffness, natriuretic-peptide and vagal-tone explanations in earlier versions of this entry were not in the abstract and are not claimed here.
Application
In 16 well-trained cyclists (VO2peak ~67-68 mL/kg/min), 8 weeks of fish oil (8 × 1 g/day, double-blind vs olive oil) lowered heart rate during incremental exercise including peak HR (P < 0.05) and lowered steady-state heart rate, whole-body O2 consumption and rate-pressure product at 55% of peak workload (P < 0.01), with no change in VO2peak, peak workload or time to fatigue (parallel RCT, Peoples 2008).
Expect a lower heart rate at a given power after several weeks of fish oil, not more power: this is a reason to re-anchor HR-based zones, and a reason not to read a lower training HR as detraining or as a fitness gain if a supplement was started.
The performance outcome (time to fatigue) did not change, so the effect is economy and cardiac O2 demand, not a direct ergogenic gain — consistent with the ISSN position (REF-188) on cardiovascular function.
Small parallel groups (7 vs 9) and no magnitudes in the abstract: a direction-of-effect study, replicated in principle by the ISSN's broader reading but not a dosing reference.
Limitations
From the design as the abstract reports it: a randomized, double-blind, parallel trial, but small — control n = 7, fish oil n = 9 completers, all well-trained men (cyclists).
The groups differed in mean age (control 27.1 ± 2.7 vs fish oil 23.2 ± 1.2 years).
One dose and duration: 8 x 1 g capsules per day for 8 weeks, olive oil as control.
Myocardial O2 demand was assessed indirectly (heart rate and rate pressure product); the performance measures (VO2peak, peak workload, time to voluntary fatigue) did not change.
How this entry was checked and changed
Content correction 2026-09-27
Groups "n=8 / n=8, age 28 ± 2, VO2max 58 ± 3" -> abstract: control n=7 (27.1 ± 2.7 y), fish oil n=9 (23.2 ± 1.2 y), VO2peak 66.8-68.3 mL/kg/min.
"3 capsules/day (~1.5 g EPA + 0.9 g DHA)" -> 8 × 1 g capsules/day, EPA/DHA content not in abstract. "Incremental 20 W/3 min steps at weeks 0, 4, 8" -> VO2peak test plus sustained submaximal test at 55% peak workload, before and after only.
Results table (HR 142 vs 148 and 176 vs 183 bpm, VO2 42.1 vs 43.8, VO2peak 62.1 vs 60.2, peak workload 385 vs 390 W, all p-values) deleted: none of these values is in the abstract; replaced by the abstract's direction-and-P results. "3-6 bpm reduction" deleted.
Molecular mechanisms (2,3-DPG, ANP, arterial stiffness, vagal tone) deleted; Level B+ -> B (parallel RCT n=16); Tier "mixed 2-3 (review)" -> Tier 3.
Cross-reference descriptions checked against the cited entries' current content; wrong years, wrong entries and claims the cited entry does not make were corrected.
2026-09-28: added Limitations from the abstract (Europe PMC, DOI 10.1097/FJC.0b013e3181911913, PMID 19034030).